Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Identifying MAGE-A4-positive tumors for TCR T cell therapies in HLA-A∗02-eligible patients.
Wang T, Navenot JM, Rafail S, Kurtis C, Carroll M, Van Kerckhoven M, Van Rossom S, Schats K, Avraam K, Broad R, Howe K, Liddle A, Clayton A, Wang R, Quinn L, Sanderson JP, McAlpine C, Carozza C, Pimpinella E, Hsu S, Brophy F, Elefant E, Bayer P, Williams D, Butler MO, Clarke JM, Gainor JF, Govindan R, Moreno V, Johnson M, Tu J, Hong DS, Blumenschein GR Jr. Wang T, et al. Among authors: sanderson jp. Mol Ther Methods Clin Dev. 2024 May 14;32(2):101265. doi: 10.1016/j.omtm.2024.101265. eCollection 2024 Jun 13. Mol Ther Methods Clin Dev. 2024. PMID: 38872830 Free PMC article.
Enhancing Efficacy of TCR-engineered CD4 + T Cells Via Coexpression of CD8α.
Anderson VE, Brilha SS, Weber AM, Pachnio A, Wiedermann GE, Dauleh S, Ahmed T, Pope GR, Quinn LL, Docta RY, Quattrini A, Masters S, Cartwright N, Viswanathan P, Melchiori L, Rice LV, Sevko A, Gueguen C, Saini M, Tavano B, Abbott RJM, Silk JD, Laugel B, Sanderson JP, Gerry AB. Anderson VE, et al. Among authors: sanderson jp. J Immunother. 2023 May 1;46(4):132-144. doi: 10.1097/CJI.0000000000000456. Epub 2023 Feb 27. J Immunother. 2023. PMID: 36826388 Free PMC article.
Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR Jr, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO. Hong DS, et al. Among authors: sanderson jp. Nat Med. 2023 Jan;29(1):104-114. doi: 10.1038/s41591-022-02128-z. Epub 2023 Jan 9. Nat Med. 2023. PMID: 36624315 Free PMC article. Clinical Trial.
Phase 1 Clinical Trial Evaluating the Safety and Anti-Tumor Activity of ADP-A2M10 SPEAR T-Cells in Patients With MAGE-A10+ Head and Neck, Melanoma, or Urothelial Tumors.
Hong DS, Butler MO, Pachynski RK, Sullivan R, Kebriaei P, Boross-Harmer S, Ghobadi A, Frigault MJ, Dumbrava EE, Sauer A, Brophy F, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou DG, Wang R, Solis LM, Duose DY, Sanderson JP, Gerry AB, Marks D, Bai J, Norry E, Fracasso PM. Hong DS, et al. Among authors: sanderson jp. Front Oncol. 2022 Mar 18;12:818679. doi: 10.3389/fonc.2022.818679. eCollection 2022. Front Oncol. 2022. PMID: 35372008 Free PMC article.
Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer.
Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, Heymach JV, Govindan R, Bachier C, Doger de Spéville B, Frigault MJ, Olszanski AJ, Lam VK, Hyland N, Navenot JM, Fayngerts S, Wolchinsky Z, Broad R, Batrakou D, Pentony MM, Sanderson JP, Gerry A, Marks D, Bai J, Holdich T, Norry E, Fracasso PM. Blumenschein GR, et al. Among authors: sanderson jp. J Immunother Cancer. 2022 Jan;10(1):e003581. doi: 10.1136/jitc-2021-003581. J Immunother Cancer. 2022. PMID: 35086946 Free PMC article. Clinical Trial.
Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β.
Silk JD, Abbott RJM, Adams KJ, Bennett AD, Brett S, Cornforth TV, Crossland KL, Figueroa DJ, Jing J, O'Connor C, Pachnio A, Patasic L, Peredo CE, Quattrini A, Quinn LL, Rust AG, Saini M, Sanderson JP, Steiner D, Tavano B, Viswanathan P, Wiedermann GE, Wong R, Jakobsen BK, Britten CM, Gerry AB, Brewer JE. Silk JD, et al. Among authors: sanderson jp. J Immunol. 2022 Jan 1;208(1):169-180. doi: 10.4049/jimmunol.2001357. Epub 2021 Dec 1. J Immunol. 2022. PMID: 34853077
Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy.
Sanderson JP, Crowley DJ, Wiedermann GE, Quinn LL, Crossland KL, Tunbridge HM, Cornforth TV, Barnes CS, Ahmed T, Howe K, Saini M, Abbott RJ, Anderson VE, Tavano B, Maroto M, Gerry AB. Sanderson JP, et al. Oncoimmunology. 2019 Nov 24;9(1):1682381. doi: 10.1080/2162402X.2019.1682381. eCollection 2020. Oncoimmunology. 2019. PMID: 32002290 Free PMC article.
Tuning T-Cell Receptor Affinity to Optimize Clinical Risk-Benefit When Targeting Alpha-Fetoprotein-Positive Liver Cancer.
Docta RY, Ferronha T, Sanderson JP, Weissensteiner T, Pope GR, Bennett AD, Pumphrey NJ, Ferjentsik Z, Quinn LL, Wiedermann GE, Anderson VE, Saini M, Maroto M, Norry E, Gerry AB. Docta RY, et al. Among authors: sanderson jp. Hepatology. 2019 May;69(5):2061-2075. doi: 10.1002/hep.30477. Epub 2019 Feb 14. Hepatology. 2019. PMID: 30561769 Free PMC article.
46 results